

Brentuximab vedotin for untreated advanced Hodgkin lymphoma (terminated appraisal)

Technology appraisal guidance

Published: 14 August 2019

www.nice.org.uk/guidance/ta594

Contents

Advice.....	3
Information.....	3

Advice

NICE is unable to make a recommendation about the use in the NHS of brentuximab vedotin for untreated advanced Hodgkin lymphoma. This is because Takeda did not provide an evidence submission. They consider that there is not enough evidence to provide an evidence submission for this appraisal.

Information

If NHS organisations wish to consider brentuximab vedotin for untreated advanced Hodgkin lymphoma, they should follow the advice on rational local decision making in the [NHS Constitution for England](#) and the [NHS Commissioning Board and Clinical Commissioning Groups \(Responsibilities and Standing Rules\) Regulations 2012](#). This outlines the approach that should be taken when there is no NICE guidance.

NICE will review the position if the company decides that it wants to make an evidence submission.

ISBN: 978-1-4731-3488-1